GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Genentech, Inc.
Study ID
NCT01332604
Phase
PHASE1
Status
Completed

Conditions

  • Solid Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GDC-0980 — DRUG
    Oral escalating dose
  • bevacizumab — DRUG
    Intravenous repeating dose
  • capecitabine — DRUG
    Oral repeating dose
  • mFOLFOX6 — DRUG
    Intravenous repeating dose

Study Details

This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0980 administered in combination with capecitabine and with mFOLFOX6 chemotherapy with bevacizumab added on at Cycle 5 in patients with advanced or metastatic solid tumors.

Key Dates

First listed
Apr 11, 2011
Start date
Jul 31, 2011
Status verified
Nov 2016
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A
  • Experimental: B

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 30 days after last dose of study treatment ]

Locations (3)

FacilityCityStateZIPSite coordinators
-Los AngelesCalifornia90095-
-AuroraColorado80045-
-RochesterMinnesota55905-

Related Studies